title: Relationship between circulating soluble Fas ligand and preexisting left ventricular hypertrophy in the setting of left ventricular remodeling after acute myocardial infarction.
abstract: OBJECTIVE
  We aimed to investigate the effects of preexisting left ventricular hypertrophy (LVH) on the circulating concentration of soluble Fas ligand (sFasL) and also the relationship of sFasL to ventricular remodeling in patients with acute myocardial infarction (MI).
  
  
  METHODS
  Forty consecutive patients who presented with their first episode of acute MI were studied. These patients were then divided into two groups with regard to the presence of LVH. All the patients underwent complete transthoracic echocardiography with determination of end diastolic volume index and LV mass index within 24 h and at 6 months. sFasL levels were determined in serum on admission and at 24 h of admission.
  
  
  RESULTS
  The serum sFasL concentration did not change significantly after acute MI at 24 h after admission in the study population (P=0.574), however, the serum level of sFasL concentration was significantly increased in the patients with preexisting LVH (P<0.001). There was a strong positive relationship between LV mass index and the serum level of sFasL concentration at 24 h after admission (r=0.611; P<0.001). Moreover, there was a stronger correlation between the change in end-diastolic volume index at 6 months and the serum level of sFasL in the LVH group compared with the group without LVH (r=0.499 and 0.181, respectively).
  
  
  CONCLUSIONS
  In conclusion, we have shown that serum sFasL concentration at 24 h after admission was significantly higher in patients with LVH, and also, there is a close relationship between the serum level of sFasL and LV enlargement.
authors.affiliation: Department of Cardiology, Memorial Hospital, Turkey. ozlembat@hotmail.com
authors.forename: Ozlem
authors.initials: O
authors.lastname: Esen
authors.forename: Hicaz Zencirkiran
authors.initials: HZ
authors.lastname: Ağuş
authors.forename: Gamze Babur
authors.initials: GB
authors.lastname: Güler
authors.forename: Göksel
authors.initials: G
authors.lastname: Açar
authors.forename: Anil
authors.initials: A
authors.lastname: Avci
authors.forename: Ekrem
authors.initials: E
authors.lastname: Güler
authors.forename: Oğuz
authors.initials: O
authors.lastname: Karaca
authors.forename: Cetin
authors.initials: C
authors.lastname: Geçmen
authors.forename: Mustafa
authors.initials: M
authors.lastname: Bulut
authors.forename: Yunus
authors.initials: Y
authors.lastname: Emiroğlu
authors.forename: Ali Metin
authors.initials: AM
authors.lastname: Esen
mesh_terms: D000328:Adult; D000368:Aged; D004452:Echocardiography; D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein / Q000097:blood*; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000503:physiopathology*; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: D053222:Fas Ligand Protein